2025 Rockville Patient and Family Conference
The 2025 Patient and Family Conference in Rockville, MD was held on March 8, 2025.
Below are links to conference session recordings in full.
patient
Putting Treatment Behind Him: Webb's Journey through Aplastic Anemia
Webb was in university, playing soccer, when he started noticing a rash and breathlessness during a run. He’d never had either symptom, particularly since he was in such good shape, playing soccer since the age of three.
ASH 2024 Update: Aplastic Anemia and PNH
Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Aplastic Anemia
Presenter(s)
Taha Bat, MD
In this webinar, Dr. Taha Bat discusses research most relevant to patients reported over the past year on the biology and treatment on Aplastic Anemia and PNH. These studies were presented at the American Society of Hematology (ASH) 2024 meeting and their findings will be…
ASH 2024 Update: MDS and AML
Topic(s)
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
Presenter(s)
Akriti Jain, MD
In this webinar, Dr. Akriti Jain discusses research most relevant to patients reported over the past year on the biology and treatment on MDS and AML. These studies were presented at the American Society of Hematology (ASH) 2024 meeting and their findings will be explained along…
Bharadhwaj Kolipakkam, MD
Institution
VCU Health
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Michael Jaglal, MD
Institution
Moffitt Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Can JAK inhibition prevent GVHD?
Original Publication Date
Article Source
External Web Content
In this issue of Blood, Pidala et al report on the results of a multicenter phase 2 trial, in which a graft-versus-host disease (GVHD) prevention regimen of pacritinib, an oral JAK2 inhibitor, in combination with sirolimus and tacrolimus successfully suppressed pSTAT3 signaling…